| Literature DB >> 35684385 |
Paulina Sokołowska1, Małgorzata Siatkowska2, Marta Jóźwiak-Bębenista1, Piotr Komorowski2,3, Marta Koptas4, Edward Kowalczyk1, Anna Wiktorowska-Owczarek1.
Abstract
Diclofenac belongs to the class of nonsteroidal anti-inflammatory drugs (NSAIDs), which are amongst the most frequently prescribed drugs to treat fever, pain and inflammation. Despite the presence of NSAIDs on the pharmaceutical market for several decades, epidemiological studies have shown new clinical applications of NSAIDs, and new mechanisms of their action were discovered. The unfolded protein response (UPR) activated under endoplasmic reticulum (ER) stress is involved in the pathophysiology of many diseases and may become a drug target, therefore, the study evaluated the effects of diclofenac on the tunicamycin-induced UPR pathways in endothelial cells. RT PCR analysis showed that diclofenac significantly inhibited activation of ER stress-responsive genes, i.e., CHOP/DITT3, GRP78/HSPA5 and DNAJB9. Additionally, the drug diminished the significant upregulation and release of the GRP78 protein, as evaluated using the ELISA assay, which was likely to be involved in the mechanism of the UPR activation resulting in apoptosis induction in endothelial cells. These results suggest the value of diclofenac as a factor capable of restoring the ER homeostasis in endothelial cells by diminishing the UPR.Entities:
Keywords: CHOP/DITT3; ER stress; GRP78/HSPA5; endothelial cells; nonsteroidal anti-inflammatory drugs (NSAIDs); unfolded protein response
Mesh:
Substances:
Year: 2022 PMID: 35684385 PMCID: PMC9182461 DOI: 10.3390/molecules27113449
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Genes and their function in ER stress signaling chosen for Real-Time PCR experiments.
| Gene Symbol | Gene Name | Function in ER Stress Signaling | Reference |
|---|---|---|---|
|
| Activating transcription factor 4 | Downstream target of PERK, which drives expression of adaptive, pro-survival genes. Under sustained stress it also activates genes involved in cell death | [ |
|
| Activating transcription factor 6 | A sensor of ER stress, activates transcription of genes maintaining ER homeostasis, i.e., gene expression of ER chaperones, ERAD components | [ |
|
| Activating transcription factor 6 beta | An inhibitor of UPR genes induced by ATF6α | [ |
|
| BCL2 associated X gene | Controls the release of cytochrome c during activation of ER-related mitochondrial apoptosis | [ |
|
| B-cell lymphoma 2 | Regulates store-operated Ca 2+ entry to prevent ER stress-induced apoptosis | [ |
|
| C/EBP homologous protein/ | Main transcription factor involved in regulation of apoptosis during ER stress. The ATF4-CHOP pathway increases the expression of other proapoptotic genes | [ |
|
| DnaJ heat shock protein family (Hsp40) member B9 | The ER luminal co-chaperone inhibits IRE1 by promoting a complex between GRP78 and the luminal stress sensing domain of IRE1α. | [ |
|
| Eukaryotic translation initiation factor 2 alpha | Directly activated by PERK (a sensor of ER stress), causes general inhibition of protein synthesis and promotes ATF4 protein production. It can also directly enhance the translation of CHOP | [ |
|
| Endoplasmic reticulum to nucleus signaling 1 | Encodes inositol-requiring enzyme 1 α (IRE1α)—a sensor of ER stress. IRE1-mediated splicing of XBP1 mRNA results in transcription of pro-survival factors | [ |
|
| Heat shock protein family (Hsp70) member 5 | The ER chaperone, plays a role in fine-tuning of the UPR—reduces ER stress and increases cell survival. When translocated to the cell surface it acts as a multifunctional receptor. | [ |
|
| Mitogen-activated protein kinase 8/ (c-Jun N-amino-terminal kinase JNK1) | Regulates several BCL-2 family members, including the activation of proapoptotic BID and BIM, and inhibition of antiapoptotic BCL-2, BCL-XL and MCL-1 | [ |
|
| TNF receptor-associated factor 2 | Activates apoptosis signal-regulating kinase 1 (ASK1) and its downstream targets c-Jun NH2-terminal kinase (JNK) and p38 MAPK | [ |
Figure 1Effect of tunicamycin (A) and diclofenac (B) on the viability of endothelial cells evaluated using MTT assay. Data are presented as mean ± SD and expressed as percentage of untreated control cells (n = 4). Statistical significance vs. control cells is indicated when appropriate; * p < 0.05; **** p < 0.0001. The results were tested by one-way ANOVA followed by post hoc Tukey’s multiple comparisons test.
Figure 2Effect of diclofenac on the viability of tunicamycin-treated endothelial cells evaluated using MTT assay. Data are presented as mean ± SD and expressed as percentage of untreated control cells (n = 4) Statistical significance vs. control cells is indicated when appropriate; ** p < 0.05; *** p < 0.001; **** p < 0.0001. The results were tested by one-way ANOVA followed by post hoc Tukey’s multiple comparisons test.
Figure 3Effect of diclofenac on gene expression of tunicamycin-treated endothelial cells evaluated using RT-PCR. Data are presented as mean ± SD and expressed as fold change vs. untreated control cells (n = 3). Statistical significance vs. tunicamycin-treated cells is indicated when appropriate; *** p < 0.001; **** p < 0.0001. The results were tested by one-way ANOVA followed by post hoc Tukey’s multiple comparisons test.
Figure 4Effect of diclofenac on expression/release of GRP78 evaluated using ELISA assay (A) and expression of CHOP evaluated using Western blot (B) proteins of tunicamycin-treated endothelial cells. Total protein normalization was performed without housekeeping proteins using stain-free total protein normalization technology. Data are presented as mean ± SD and expressed as percentage of untreated control cells (A n = 3; B n = 4). Statistical significance vs. control cells is indicated when appropriate; * p < 0.05 vs. untreated control ** p < 0.01 vs. untreated control; # p < 0.05 vs. tunicamycin-treated cells. The results were tested by one-way ANOVA followed by post hoc Tukey’s multiple comparisons test.
Figure 5Effect of diclofenac on apoptosis evoked by tunicamycin in endothelial cells evaluated using the Annexin V test. Data are presented as mean ± SD and expressed as a percentage of untreated control cells (n = 3). Statistical significance vs. control cells is indicated when appropriate; **** p < 0.0001 vs. untreated control; #### p < 0.0001 vs. tunicamycin-treated cell. The results were tested by one-way ANOVA followed by post hoc Tukey’s multiple comparisons test.